Switch to:
Also traded in: Argentina, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.40
NYSE:MDT's Cash to Debt is ranked lower than
80% of the 320 Companies
in the Global Medical Devices industry.

( Industry Median: 2.19 vs. NYSE:MDT: 0.40 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:MDT' s Cash to Debt Range Over the Past 10 Years
Min: 0.15  Med: 0.62 Max: 9.58
Current: 0.4
0.15
9.58
Equity to Asset 0.52
NYSE:MDT's Equity to Asset is ranked lower than
66% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. NYSE:MDT: 0.52 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:MDT' s Equity to Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.57 Max: 0.82
Current: 0.52
0.37
0.82
Interest Coverage 3.94
NYSE:MDT's Interest Coverage is ranked lower than
87% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: 69.16 vs. NYSE:MDT: 3.94 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:MDT' s Interest Coverage Range Over the Past 10 Years
Min: 3.82  Med: 10.69 Max: 16.28
Current: 3.94
3.82
16.28
F-Score: 6
Z-Score: 2.95
M-Score: -2.48
WACC vs ROIC
7.38%
6.32%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 18.54
NYSE:MDT's Operating margin (%) is ranked higher than
87% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 2.72 vs. NYSE:MDT: 18.54 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:MDT' s Operating margin (%) Range Over the Past 10 Years
Min: 16.71  Med: 23.03 Max: 30.17
Current: 18.54
16.71
30.17
Net-margin (%) 12.70
NYSE:MDT's Net-margin (%) is ranked higher than
82% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 1.24 vs. NYSE:MDT: 12.70 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:MDT' s Net-margin (%) Range Over the Past 10 Years
Min: 12.27  Med: 18.81 Max: 22.78
Current: 12.7
12.27
22.78
ROE (%) 7.05
NYSE:MDT's ROE (%) is ranked higher than
63% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. NYSE:MDT: 7.05 )
Ranked among companies with meaningful ROE (%) only.
NYSE:MDT' s ROE (%) Range Over the Past 10 Years
Min: 6.72  Med: 19.6 Max: 27.52
Current: 7.05
6.72
27.52
ROA (%) 3.57
NYSE:MDT's ROA (%) is ranked higher than
63% of the 322 Companies
in the Global Medical Devices industry.

( Industry Median: 0.05 vs. NYSE:MDT: 3.57 )
Ranked among companies with meaningful ROA (%) only.
NYSE:MDT' s ROA (%) Range Over the Past 10 Years
Min: 3.43  Med: 10.41 Max: 14.3
Current: 3.57
3.43
14.3
ROC (Joel Greenblatt) (%) 59.32
NYSE:MDT's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 4.17 vs. NYSE:MDT: 59.32 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:MDT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 51.21  Med: 66.98 Max: 82.85
Current: 59.32
51.21
82.85
Revenue Growth (3Y)(%) 7.80
NYSE:MDT's Revenue Growth (3Y)(%) is ranked higher than
68% of the 232 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. NYSE:MDT: 7.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:MDT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 4.2  Med: 12.6 Max: 17.9
Current: 7.8
4.2
17.9
EBITDA Growth (3Y)(%) 4.10
NYSE:MDT's EBITDA Growth (3Y)(%) is ranked higher than
54% of the 192 Companies
in the Global Medical Devices industry.

( Industry Median: 1.50 vs. NYSE:MDT: 4.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:MDT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -15.5  Med: 9.6 Max: 24
Current: 4.1
-15.5
24
EPS Growth (3Y)(%) -9.70
NYSE:MDT's EPS Growth (3Y)(%) is ranked lower than
70% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. NYSE:MDT: -9.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:MDT' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -9.7  Med: 13.5 Max: 27.1
Current: -9.7
-9.7
27.1
» NYSE:MDT's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-12-03)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

MDT Guru Trades in Q3 2015

Jim Simons 531,441 sh (New)
Joel Greenblatt 10,247 sh (New)
Paul Tudor Jones 151,700 sh (New)
Manning & Napier Advisors, Inc 2,671,920 sh (New)
First Eagle Investment 17,735 sh (+39.26%)
Vanguard Health Care Fund 20,081,233 sh (+6.33%)
Ruane Cunniff 5,075 sh (+4.00%)
John Buckingham 21,140 sh (+3.85%)
Pioneer Investments 2,451,935 sh (+3.16%)
Keeley Asset Management Corp 40,520 sh (unchged)
John Hussman 175,000 sh (unchged)
Bill Nygren 4,190,000 sh (unchged)
Robert Olstein 134,000 sh (unchged)
David Carlson 830,000 sh (unchged)
John Burbank Sold Out
Steven Romick Sold Out
First Pacific Advisors Sold Out
Jeff Auxier 139,473 sh (-0.08%)
Ronald Muhlenkamp 173,364 sh (-0.22%)
Mairs and Power 3,171,922 sh (-1.29%)
Barrow, Hanley, Mewhinney & Strauss 30,967,127 sh (-2.05%)
Diamond Hill Capital 3,466,464 sh (-2.37%)
Jeremy Grantham 7,197,272 sh (-4.62%)
HOTCHKIS & WILEY 5,290,450 sh (-5.86%)
PRIMECAP Management 15,260,876 sh (-6.92%)
Ken Fisher 5,939 sh (-7.85%)
Dodge & Cox 6,971,380 sh (-12.99%)
Steven Cohen 500,900 sh (-16.01%)
Mario Gabelli 46,079 sh (-30.13%)
Ray Dalio 57,186 sh (-32.83%)
» More
Q4 2015

MDT Guru Trades in Q4 2015

Louis Moore Bacon 375,000 sh (New)
First Eagle Investment 1,940,036 sh (+10839.02%)
Manning & Napier Advisors, Inc 5,016,210 sh (+87.74%)
Pioneer Investments 4,269,571 sh (+74.13%)
David Carlson 900,000 sh (+8.43%)
John Buckingham 22,788 sh (+7.80%)
Vanguard Health Care Fund 20,081,233 sh (unchged)
Ruane Cunniff 5,075 sh (unchged)
Bill Nygren 4,190,000 sh (unchged)
John Hussman 175,000 sh (unchged)
Ronald Muhlenkamp Sold Out
Jim Simons Sold Out
Jeff Auxier 139,273 sh (-0.14%)
PRIMECAP Management 15,187,651 sh (-0.48%)
Ken Fisher 5,905 sh (-0.57%)
Diamond Hill Capital 3,436,197 sh (-0.87%)
Mairs and Power 3,143,155 sh (-0.91%)
Dodge & Cox 6,867,935 sh (-1.48%)
Barrow, Hanley, Mewhinney & Strauss 30,282,119 sh (-2.21%)
Ray Dalio 53,186 sh (-6.99%)
Steven Cohen 461,800 sh (-7.81%)
Mario Gabelli 40,111 sh (-12.95%)
Robert Olstein 108,000 sh (-19.40%)
HOTCHKIS & WILEY 3,880,914 sh (-26.64%)
Jeremy Grantham 4,545,540 sh (-36.84%)
Keeley Asset Management Corp 25,281 sh (-37.61%)
Joel Greenblatt 2,705 sh (-73.60%)
Paul Tudor Jones 3,200 sh (-97.89%)
» More
Q1 2016

MDT Guru Trades in Q1 2016

George Soros 11,100 sh (New)
Signature Select Canadian Fund 126,900 sh (New)
Manning & Napier Advisors, Inc 7,795,870 sh (+55.41%)
Pioneer Investments 4,619,992 sh (+8.21%)
David Carlson 930,000 sh (+3.33%)
John Buckingham 23,323 sh (+2.35%)
Jeff Auxier 139,773 sh (+0.36%)
PRIMECAP Management 15,196,981 sh (+0.06%)
Louis Moore Bacon 50,000 sh (unchged)
John Hussman 175,000 sh (unchged)
Louis Moore Bacon Sold Out
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Ray Dalio Sold Out
Joel Greenblatt Sold Out
Dodge & Cox 6,838,035 sh (-0.44%)
Mairs and Power 3,017,700 sh (-3.99%)
First Eagle Investment 1,833,793 sh (-5.48%)
Mario Gabelli 37,877 sh (-5.57%)
Vanguard Health Care Fund 18,332,133 sh (-8.71%)
Barrow, Hanley, Mewhinney & Strauss 27,494,507 sh (-9.21%)
Robert Olstein 96,000 sh (-11.11%)
Ken Fisher 5,018 sh (-15.02%)
Jeremy Grantham 3,706,658 sh (-18.46%)
Ruane Cunniff 3,895 sh (-23.25%)
Diamond Hill Capital 2,515,263 sh (-26.80%)
HOTCHKIS & WILEY 2,374,011 sh (-38.83%)
Bill Nygren 2,490,000 sh (-40.57%)
Keeley Asset Management Corp 12,172 sh (-51.85%)
» More
Q2 2016

MDT Guru Trades in Q2 2016

Jim Simons 573,141 sh (New)
T Rowe Price Equity Income Fund 750,000 sh (New)
Steven Cohen 125,000 sh (New)
Paul Tudor Jones 4,000 sh (New)
Joel Greenblatt 167,825 sh (New)
Jeremy Grantham 4,444,824 sh (+19.91%)
Pioneer Investments 4,975,460 sh (+7.69%)
Vanguard Health Care Fund 19,159,633 sh (+4.51%)
Bill Nygren 2,490,000 sh (unchged)
David Carlson 930,000 sh (unchged)
George Soros Sold Out
Jeff Auxier 139,173 sh (-0.43%)
Mairs and Power 2,994,818 sh (-0.76%)
PRIMECAP Management 14,981,004 sh (-1.42%)
Diamond Hill Capital 2,470,305 sh (-1.79%)
Dodge & Cox 6,452,264 sh (-5.64%)
Ken Fisher 4,716 sh (-6.02%)
John Buckingham 21,869 sh (-6.23%)
Keeley Asset Management Corp 11,133 sh (-8.54%)
Manning & Napier Advisors, Inc 7,062,815 sh (-9.40%)
Mario Gabelli 34,285 sh (-9.48%)
Ruane Cunniff 3,395 sh (-12.84%)
Barrow, Hanley, Mewhinney & Strauss 21,090,262 sh (-23.29%)
John Hussman 125,000 sh (-28.57%)
HOTCHKIS & WILEY 1,653,662 sh (-30.34%)
Robert Olstein 66,000 sh (-31.25%)
First Eagle Investment 1,106,014 sh (-39.69%)
» More
» Details

Insider Trades

Latest Guru Trades with MDT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NYSE:ABT, NYSE:SYK, NYSE:BSX, NAS:ISRG, NYSE:ZBH, NYSE:EW, NYSE:STJ, OTCPK:SNNUF, OTCPK:SONVY, NYSE:VAR, NYSE:TFX, NAS:ALGN, OTCPK:SDMHF, OTCPK:CHEOY, OTCPK:WILLF, NAS:ABMD, OTCPK:FSPKF, OTCPK:EKTAF, NAS:NUVA, OTCPK:GGNDF » details
Traded in other countries:MDT.Argentina, MDTC34.Brazil, 2M6.Germany, MDT N.Mexico, MDT.Switzerland, 0QYG.UK,
Medtronic PLC is engaged in providing medical technology alleviating pain, restoring health, and extending life of people. It currently functions in three operating segments that manufacture and sell device-based medical therapies.

Medtronic PLC was founded in 1949, incorporated as a Minnesota corporation in 1957. The Company is a medical technology company - alleviating pain, restoring health, and extending life for millions of people around the world. Its primary products include those for cardiac rhythm disorders, cardiovascular disease, neurological disorders, spinal conditions and musculoskeletal trauma, urological and digestive disorders, and ear, nose, and throat and diabetes conditions. The Company functions in four operating segments that manufacture and sell device-based medical therapies: Cardiac and Vascular Group; Minimally Invasive Therapies Group; Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group includes Cardiac Rhythm Disease Management that develops, manufactures, and markets products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure, including implantable devices, leads and delivery systems, products for the treatment of atrial fibrillation (AF), products designed to reduce surgical site infections, information systems for the management of patients with CRDM devices, and an integrated health solutions business; Coronary which includes therapies to treat coronary artery disease (CAD) and hypertension. The products contained within this business include coronary stents and related delivery systems, including a broad line of balloon angioplasty catheters, guide catheters, guidewires, diagnostic catheters, and accessories; The Structural Heart business offers a comprehensive line of products and therapies to treat a variety of heart valve disorders. The Endovascular business is comprised of a comprehensive line of products and therapies to treat aortic disease (such as aneurysms, dissections, and transections) as well as peripheral vascular disease (PVD). Its products include endovascular stent graft systems, peripheral stent and angioplasty systems, and carotid embolic protection systems for the treatment of vascular disease outside the heart. The Minimally Invasive Therapies Group is composed of the Surgical Solutions and Patient Monitoring & Recovery divisions. With a focus on diseases of the gastrointestinal tract, lungs, pelvic region, kidneys, obesity, and preventable complications, the group looks to enhance patient outcomes through minimally invasive solutions. The Restorative Therapies Group includes Spine business which develops, manufactures, and markets a comprehensive line of medical devices and implants used in the treatment of the spine and musculoskeletal system. Its products and therapies treat a variety of conditions affecting the spine, including degenerative disc disease, spinal deformity, spinal tumors, fractures of the spine, and stenosis. Its Spine business also provides biologic solutions for the orthopedic and dental markets. Its Neuromodulation business includes implantable neurostimulation and targeted drug delivery systems for the management of ch

Ratios

vs
industry
vs
history
P/E(ttm) 33.68
MDT's P/E(ttm) is ranked lower than
60% of the 167 Companies
in the Global Medical Devices industry.

( Industry Median: 27.08 vs. MDT: 33.68 )
Ranked among companies with meaningful P/E(ttm) only.
MDT' s P/E(ttm) Range Over the Past 10 Years
Min: 10.17  Med: 20.53 Max: 54.09
Current: 33.68
10.17
54.09
Forward P/E 18.83
MDT's Forward P/E is ranked higher than
73% of the 56 Companies
in the Global Medical Devices industry.

( Industry Median: 23.87 vs. MDT: 18.83 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 33.68
MDT's PE(NRI) is ranked lower than
59% of the 167 Companies
in the Global Medical Devices industry.

( Industry Median: 27.22 vs. MDT: 33.68 )
Ranked among companies with meaningful PE(NRI) only.
MDT' s PE(NRI) Range Over the Past 10 Years
Min: 10.17  Med: 20.53 Max: 54.09
Current: 33.68
10.17
54.09
Price/Owner Earnings (ttm) 23.76
MDT's Price/Owner Earnings (ttm) is ranked higher than
62% of the 109 Companies
in the Global Medical Devices industry.

( Industry Median: 31.34 vs. MDT: 23.76 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MDT' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.24  Med: 19.17 Max: 92.5
Current: 23.76
9.24
92.5
P/B 2.39
MDT's P/B is ranked higher than
61% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 3.05 vs. MDT: 2.39 )
Ranked among companies with meaningful P/B only.
MDT' s P/B Range Over the Past 10 Years
Min: 1.78  Med: 2.93 Max: 6.3
Current: 2.39
1.78
6.3
P/S 4.25
MDT's P/S is ranked lower than
62% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 3.23 vs. MDT: 4.25 )
Ranked among companies with meaningful P/S only.
MDT' s P/S Range Over the Past 10 Years
Min: 1.93  Med: 3.49 Max: 6.55
Current: 4.25
1.93
6.55
PFCF 25.64
MDT's PFCF is ranked higher than
58% of the 100 Companies
in the Global Medical Devices industry.

( Industry Median: 30.18 vs. MDT: 25.64 )
Ranked among companies with meaningful PFCF only.
MDT' s PFCF Range Over the Past 10 Years
Min: 9.19  Med: 14.91 Max: 70.14
Current: 25.64
9.19
70.14
POCF 20.64
MDT's POCF is ranked higher than
52% of the 132 Companies
in the Global Medical Devices industry.

( Industry Median: 21.53 vs. MDT: 20.64 )
Ranked among companies with meaningful POCF only.
MDT' s POCF Range Over the Past 10 Years
Min: 8.14  Med: 12.98 Max: 31.21
Current: 20.64
8.14
31.21
EV-to-EBIT 24.21
MDT's EV-to-EBIT is ranked lower than
54% of the 164 Companies
in the Global Medical Devices industry.

( Industry Median: 22.51 vs. MDT: 24.21 )
Ranked among companies with meaningful EV-to-EBIT only.
MDT' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.7  Med: 15.8 Max: 30.9
Current: 24.21
8.7
30.9
EV-to-EBITDA 16.16
MDT's EV-to-EBITDA is ranked higher than
52% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 16.88 vs. MDT: 16.16 )
Ranked among companies with meaningful EV-to-EBITDA only.
MDT' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.4  Med: 13.3 Max: 24.9
Current: 16.16
7.4
24.9
PEG 8.32
MDT's PEG is ranked lower than
76% of the 75 Companies
in the Global Medical Devices industry.

( Industry Median: 2.80 vs. MDT: 8.32 )
Ranked among companies with meaningful PEG only.
MDT' s PEG Range Over the Past 10 Years
Min: 1.1  Med: 1.91 Max: 18.15
Current: 8.32
1.1
18.15
Shiller P/E 30.36
MDT's Shiller P/E is ranked higher than
77% of the 47 Companies
in the Global Medical Devices industry.

( Industry Median: 42.11 vs. MDT: 30.36 )
Ranked among companies with meaningful Shiller P/E only.
MDT' s Shiller P/E Range Over the Past 10 Years
Min: 14.35  Med: 22.2 Max: 44.51
Current: 30.36
14.35
44.51
Current Ratio 2.98
MDT's Current Ratio is ranked higher than
58% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 2.56 vs. MDT: 2.98 )
Ranked among companies with meaningful Current Ratio only.
MDT' s Current Ratio Range Over the Past 10 Years
Min: 0.88  Med: 2.44 Max: 6.8
Current: 2.98
0.88
6.8
Quick Ratio 2.52
MDT's Quick Ratio is ranked higher than
60% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 1.94 vs. MDT: 2.52 )
Ranked among companies with meaningful Quick Ratio only.
MDT' s Quick Ratio Range Over the Past 10 Years
Min: 0.66  Med: 1.95 Max: 6.46
Current: 2.52
0.66
6.46
Days Inventory 142.86
MDT's Days Inventory is ranked lower than
55% of the 280 Companies
in the Global Medical Devices industry.

( Industry Median: 132.35 vs. MDT: 142.86 )
Ranked among companies with meaningful Days Inventory only.
MDT' s Days Inventory Range Over the Past 10 Years
Min: 132.14  Med: 142.57 Max: 164.01
Current: 142.86
132.14
164.01
Days Sales Outstanding 68.07
MDT's Days Sales Outstanding is ranked higher than
50% of the 268 Companies
in the Global Medical Devices industry.

( Industry Median: 68.07 vs. MDT: 68.07 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 68.07  Med: 81.9 Max: 92.09
Current: 68.07
68.07
92.09
Days Payable 65.89
MDT's Days Payable is ranked higher than
55% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 57.81 vs. MDT: 65.89 )
Ranked among companies with meaningful Days Payable only.
MDT' s Days Payable Range Over the Past 10 Years
Min: 32.49  Med: 51.72 Max: 93.14
Current: 65.89
32.49
93.14

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.81
MDT's Dividend Yield is ranked higher than
58% of the 163 Companies
in the Global Medical Devices industry.

( Industry Median: 1.68 vs. MDT: 1.81 )
Ranked among companies with meaningful Dividend Yield only.
MDT' s Dividend Yield Range Over the Past 10 Years
Min: 0.62  Med: 1.86 Max: 2.93
Current: 1.81
0.62
2.93
Dividend Payout 0.61
MDT's Dividend Payout is ranked higher than
84% of the 114 Companies
in the Global Medical Devices industry.

( Industry Median: 0.39 vs. MDT: 0.61 )
Ranked among companies with meaningful Dividend Payout only.
MDT' s Dividend Payout Range Over the Past 10 Years
Min: 0.14  Med: 0.26 Max: 1.88
Current: 0.61
0.14
1.88
Dividend Growth (3y) 13.50
MDT's Dividend Growth (3y) is ranked higher than
62% of the 76 Companies
in the Global Medical Devices industry.

( Industry Median: 9.10 vs. MDT: 13.50 )
Ranked among companies with meaningful Dividend Growth (3y) only.
MDT' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 7.6  Med: 14.9 Max: 24.9
Current: 13.5
7.6
24.9
Forward Dividend Yield 1.96
MDT's Forward Dividend Yield is ranked higher than
62% of the 154 Companies
in the Global Medical Devices industry.

( Industry Median: 1.76 vs. MDT: 1.96 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 2.94
MDT's Yield on cost (5-Year) is ranked higher than
68% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. MDT: 2.94 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
MDT' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.01  Med: 3.02 Max: 4.76
Current: 2.94
1.01
4.76
3-Year Average Share Buyback Ratio -11.30
MDT's 3-Year Average Share Buyback Ratio is ranked lower than
71% of the 211 Companies
in the Global Medical Devices industry.

( Industry Median: -3.40 vs. MDT: -11.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MDT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -11.3  Med: 1 Max: 2.5
Current: -11.3
-11.3
2.5

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.39
MDT's Price/Projected FCF is ranked higher than
72% of the 123 Companies
in the Global Medical Devices industry.

( Industry Median: 2.18 vs. MDT: 1.39 )
Ranked among companies with meaningful Price/Projected FCF only.
MDT' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.76  Med: 1.41 Max: 6.95
Current: 1.39
0.76
6.95
Price/DCF (Earnings Based) 3.15
MDT's Price/DCF (Earnings Based) is ranked lower than
72% of the 18 Companies
in the Global Medical Devices industry.

( Industry Median: 2.13 vs. MDT: 3.15 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.23
MDT's Price/Median PS Value is ranked lower than
59% of the 253 Companies
in the Global Medical Devices industry.

( Industry Median: 1.06 vs. MDT: 1.23 )
Ranked among companies with meaningful Price/Median PS Value only.
MDT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.67  Med: 1.51 Max: 3.62
Current: 1.23
0.67
3.62
Earnings Yield (Greenblatt) (%) 4.15
MDT's Earnings Yield (Greenblatt) (%) is ranked higher than
72% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. MDT: 4.15 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MDT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.2  Med: 6.3 Max: 11.5
Current: 4.15
3.2
11.5
Forward Rate of Return (Yacktman) (%) 8.14
MDT's Forward Rate of Return (Yacktman) (%) is ranked higher than
52% of the 118 Companies
in the Global Medical Devices industry.

( Industry Median: 7.67 vs. MDT: 8.14 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MDT' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 7.2  Med: 14.6 Max: 19.5
Current: 8.14
7.2
19.5

More Statistics

Revenue (TTM) (Mil) $28,725
EPS (TTM) $ 2.57
Beta0.92
Short Percentage of Float0.76%
52-Week Range $63.98 - 89.27
Shares Outstanding (Mil)1,381.94

Analyst Estimate

Apr17 Apr18 Apr19
Revenue (Mil $) 30,134 31,781 34,084
EPS ($) 4.66 5.16 5.83
EPS w/o NRI ($) 4.66 5.16 5.83
EPS Growth Rate
(3Y to 5Y Estimate)
7.60%
Dividends Per Share ($) 1.65 1.90 2.28
» More Articles for NYSE:MDT

Headlines

Articles On GuruFocus.com
Barrow, Hanley, Mewhinney & Strauss Reduces Stakes in 2nd Quarter Sep 13 2016 
Dividend Aristocrat Correlation Pairs Aug 28 2016 
Jeff Auxier's Summer 2016 Market Commentary Aug 05 2016 
Gabelli Funds Comments on Medtronic Plc Aug 04 2016 
T. Rowe Price Buys Apple, Pepsi, Western Digital Jul 26 2016 
T. Rowe Price Ditches Domestic, Buys Foreign Jul 22 2016 
T Rowe Price Buys Apple and 2 Other Companies Jul 15 2016 
Baxter Well Positioned in Fast-Growing Market for Kidney Dialysis Equipment Jul 01 2016 
IBM's CEO Discusses Cognitive Computing Apr 10 2016 
The Conundrum in Health Care Investing Mar 06 2016 

More From Other Websites
Medtronic's StealthStation® Cranial Software Receives FDA Clearance as an Aid for Deep Brain... Sep 26 2016
8:02 am Medtronic recieves FDA clearance of StealthStation Cranial Software as an aid for deep brain... Sep 26 2016
ETF’s with exposure to Medtronic Plc : September 23, 2016 Sep 23 2016
Medtronic (MDT): Valiant Captivia Data Positive at Three Years Sep 23 2016
Medtronic Valiant Captivia Demonstrates Safety and Efficacy at Three Years Sep 20 2016
Medtronic Plc (MDT) Chairman & CEO Omar Ishrak Sold $5.3 million of Shares Sep 19 2016
New Data Presented in VIVA Late Breaking Clinical Trials Demonstrate Durability, Safety and Efficacy... Sep 19 2016
Analysis Shows Positive Association Between Cardiac Resynchronization Therapy and Patients'... Sep 19 2016
AxoGen, Inc. Appoints Amy Wendell to Board of Directors Sep 19 2016
Analyzing St. Jude Medical’s Latest Dividend Payment Sep 16 2016
Medtronic's Reveal Heart Monitor Launch in Japan Bodes Well Sep 15 2016
The Journal of the American Medical Association Publishes Medtronic's Hybrid Closed Loop System... Sep 15 2016
Medtronic Names Mark Ploof Senior Vice President of Global Operations and Business Services Sep 15 2016
Today's Top 5 Stock Picks: Oshkosh, Unilever, More Sep 15 2016
Medtronic IN.PACT Admiral: First FDA-Approved DCB for ISR Sep 14 2016
Medtronic Announces Approval and Launch of Reveal LINQ(TM) Insertable Cardiac Monitor in Japan Sep 14 2016
Barrow, Hanley, Mewhinney & Strauss Reduces Stakes in 2nd Quarter Sep 13 2016
Perrenial Target and Acquirer NuVasive Names New President and COO Sep 13 2016
Medtronic Receives FDA Approval of First Drug-Coated Balloon for Treatment of In-Stent Restenosis... Sep 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)